RT Journal Article
SR Electronic
T1 Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy and venous thromboembolism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.28.20184234
DO 10.1101/2020.08.28.20184234
A1 Grant Castaneda
A1 Abby C Lee
A1 Wei Tse Li
A1 Chengyu Chen
A1 Jaideep Chakladar
A1 Eric Y. Chang
A1 Weg M. Ongkeko
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.28.20184234.abstract
AB As of 28 August 2020, there have been 5.88 million Coronavirus Disease 2019 (COVID19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation that accompanies cardiovascular disease predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation in patients with cardiomyopathy, venous thromboembolism and COVID-19 patients by looking at immune-associated gene dysregulation, immune infiltration and dysregulated immunological pathways and gene signatures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded the University of California, Office of the President/Tobacco-Related Disease Research Program Emergency COVID-19 Research Seed Funding Grant (Grant number: R00RG2369) to W.M.O. and the University of California, San Diego Academic Senate Grant (Grant number: RG096651) to Weg OngkekoAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA-sequencing data was obtained from the following datasets: GSE116250, GSE19151 and SRP262885. https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP262885 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116250 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116250